Investor Presentaiton
40
Werner Inhibitor In-Vivo Efficacy in MSI-High Models
WRNi Shows Pharmacological Activity in Therapy-Refractory CRC MSI-High Models
Werner Helicase Activity in Therapy-Refractory CRC Organoid Models
Immuno-Refractory
(Genetic Sensitivity)
Immuno-Refractory
Viability (%)
sgNon
(Pharmacological Sensitivity)
sgWRN2
150-
125-
100-
Chemo-Refractory
(Genetic Sensitivity)
IRCC-114-XL
125-
www
100-
75-
50-
25-
0
sgNon sgPLK1 sgWRN1 sgWRN2
IDEAYA/GSK/Welcome Sanger Institute Data
Viability (%)
75-
50-
25-
WRNi
Immuno-sensitive
Immuno-refractory
Strategic Collaboration with GSK
US: 50%/50% Profit Share
Ex-US: Royalties tiered from high single-digit to
sub-teen double digit percentages
Milestones: ~$1B, incl up to $20M for Preclinical
through early Ph1 Clinical
Cost Share: 20% IDEAYA / 80% GSK
Strategic Rationale: Potential Combination with
GSK's Dostarlimab, a PD-1 IO Agent
ā Targeting Werner Helicase
Development Candidate in H2 2023
Pharmacological activity in therapy-
refractory models supports clinical thesis
IDEAVA
BIOSCIENCESView entire presentation